Pharmaceutical companies are getting a fresh look for a range of drugs in development, plus a regulatory reprieve.

Next week, drugmakers will arrive at the JPMorgan Healthcare Conference in San Francisco feeling far more confident than in ...

Enter generative AI, which the pharma industry is adopting at a terrific rate. By ingesting and analysing vast biological ...

With Johnson & Johnson’s participation, 15 of 17 companies contacted by the administration over the summer have now signed on ...

Johnson & Johnson said on Thursday that it has reached an agreement with U.S. President Donald Trump's administration to cut ...

Only a handful of the top pharmas have signed Most Favored Nation drug pricing deals with the White House, while smaller ...

Jazz Pharmaceuticals plc looks very undervalued at 2.4x sales as oncology catalysts (Ziihera, Zepzelca, Epidiolex) drive ...

Some of the top-grossing drugs include Merck's Keytruda, an immunotherapy for multiple cancers with almost $30 billion in ...

Drugmakers are planning to raise the prices of at least 350 drugs in 2026, despite their pledges to offer reduced prices ...

TrumpRx is supposed to launch in early 2026. Here's what we know about how buying medicine through the site to get discounts ...

The Singapore-based AI clinical trial engine powering Asia’s—especially China’s—rapid rise in the biotech industry. Deep ...